Search

Genmab A-S

Uždarymo kaina

1,864.5 -3.12

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1873.5

Max

1931.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

21M

52M

Pardavimai

-184M

881M

P/E

Sektoriaus vid.

21.697

60.549

Pelnas, tenkantis vienai akcijai

8.48

Pelno marža

5.915

Darbuotojai

3,088

EBITDA

-30M

215M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-1.49% downside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

10B

115B

Ankstesnė atidarymo kaina

1867.62

Ankstesnė uždarymo kaina

1864.5

Genmab A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-08 23:56; UTC

Sirius XM Holdings Inc shares are higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month trading range.

2026-07-08 23:56; UTC

MercadoLibre Inc. shares declined during after-market hours, reflecting broader market sentiment amid rising oil prices and inflationary pressures from Middle East tensions.

2026-07-08 23:56; UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

2026-07-08 23:52; UTC

UK House Price Balance Declines to -0.33%, Heightening Concerns Over Housing Market Stability Amid Economic Pressures

2026-07-08 23:52; UTC

Positive Shift in U.S. Home Sales Anticipated as June Data Shows 5.9% Year-over-Year Increase Ahead of July Release.

2026-07-08 23:52; UTC

Optimism Grows Ahead of July 9 Release for U.S. Existing Home Sales Amid Lower Mortgage Rates and Increased Listings

2026-07-08 23:52; UTC

Australia's Westpac Consumer Confidence Index shows a 3.5% drop, signaling ongoing economic concerns ahead of July 14 release amid inflationary pressures and market volatility.

2026-07-08 23:52; UTC

Australia's Westpac Consumer Confidence Index set for July 14, 2026 release amid cautious investor sentiment and global economic pressures.

2026-07-08 23:51; UTC

Gilead Sciences shares are lower in after-hours trading, reflecting a decline from earlier levels amid broader market weakness influenced by geopolitical tensions.

2026-07-08 23:51; UTC

News

Broadcom shares rise in after-market hours as analysts project $172 billion in revenue next year, driven by AI infrastructure spending.

2026-07-08 23:51; UTC

U.S. equity markets show mixed results amid rising oil prices and geopolitical tensions, with European markets declining sharply as inflation fears grow.

2026-07-08 23:51; UTC

Geopolitical tensions and rising oil prices drive mixed Asian equity markets, with European indices declining amid inflation concerns and revised global growth forecasts.

2026-07-08 23:51; UTC

Global equity markets decline amid rising oil prices and geopolitical tensions, with U.S. consumer credit unexpectedly falling.

2026-07-08 23:51; UTC

European equity markets drop as DAX 30 falls 2.5% amid escalating Middle East tensions, rising oil prices, and inflation concerns.

2026-07-08 23:51; UTC

Macro News
ETF Constituents
Correlated Moves

Materials Select Sector SPDR Fund declines in after-market hours amid geopolitical tensions affecting global oil markets and related asset sentiment.

2026-07-08 23:51; UTC

News
Social Media

Costco Wholesale reported net sales of $29.24 billion for June but shares declined in after-hours trading amid mixed investor sentiment and broader market trends.

2026-07-08 23:51; UTC

Correlated Moves

The NZD/HKD is higher today, reflecting a modest increase since Tuesday's close, despite declines in European markets, including the DAX 30 Index.

2026-07-08 23:51; UTC

Correlated Moves
Macro News

The New Zealand Dollar has strengthened against major currencies after the Reserve Bank raised its key interest rate to 2.50%.

2026-07-08 23:51; UTC

Macro News
ETF Constituents

iShares MSCI South Korea ETF declines in after-market hours amid KOSPI's significant drop and rising global economic concerns linked to Middle East tensions.

2026-07-08 23:51; UTC

Macro News
ETF Constituents

The iShares U.S. Aerospace & Defense ETF declined in after-market trading amid rising tensions from U.S. military strikes against Iranian targets, impacting key defense firms.

2026-07-08 23:51; UTC

Correlated Moves
Macro News

Bitcoin is trading lower amid rising geopolitical tensions following President Trump's ceasefire announcement with Iran. Earlier, it reached a session high before declining.

2026-07-08 23:46; UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting routine trading activity with minimal fluctuations and positioning above the 20-day moving average.

2026-07-08 23:46; UTC

Fastenal Co shares are trading lower in after-market hours, marking the fifth consecutive day of declines amid broader market weakness linked to geopolitical tensions.

2026-07-08 23:46; UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite significant declines in European markets amid geopolitical tensions involving the U.S. and Iran.

2026-07-08 23:46; UTC

News
ETF Constituents
Macro News
Correlated Moves

The Financial Select Sector SPDR Fund is higher in after-market trading, supported by strong seasonal patterns and movements in major bank holdings.

2026-07-08 23:46; UTC

Western Digital shares are lower in after-market trading, amid broader market declines linked to geopolitical tensions affecting oil supply routes.

2026-07-08 23:41; UTC

News
Social Media
Correlated Moves

Advanced Micro Devices shares are declining in after-hours trading amid negative sentiment in semiconductor stocks, following the announcement of its upcoming earnings report.

2026-07-08 23:41; UTC

U.S. 30-Year Mortgage Rate Rises to 6.58%, Sparking Decline in Applications Amid Inflation and Economic Uncertainty

2026-07-08 23:41; UTC

Social Media
News

NVIDIA Corp shares declined in after-market trading amid concerns over AI spending and competition. Analysts note cautious investor sentiment contributing to the bearish outlook.

2026-07-08 23:41; UTC

News
Social Media
Correlated Moves

Micron Technology shares traded higher after notable options activity, with $7.2 million in orders for $815 7/17 Puts contributing to a total premium of over $21.5 million.

Akcijų palyginimas

Kainos pokytis

Genmab A-S Prognozė

Kainos tikslas

By TipRanks

-1.49% į apačią

12 mėnesių prognozė

Vidutinis 2,493.35 DKK  -1.49%

Aukščiausias 3,320 DKK

Žemiausias 308.417 DKK

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Genmab A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

3

Pirkti

2

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat